#1 Clinical Trials Search in Europe

Specific Nucleic Acid Sna-Xfsb

This article discusses a clinical trial investigating the effectiveness of two drugs, 2LEBV® and 2LXFS®, in treating fatigue associated with Epstein-Barr Virus (EBV) infection. The study aims to compare these treatments against a placebo in reducing fatigue severity and other EBV-related symptoms. This randomized, placebo-controlled, double-blind study will provide valuable insights into potential new treatments for patients suffering from EBV-related fatigue.

Table of Contents

What is SPECIFIC NUCLEIC ACID SNA-XFSB?

SPECIFIC NUCLEIC ACID SNA-XFSB is a medical substance being studied as a potential treatment for Epstein-Barr Virus (EBV) infection[1]. It is also known by its synonym “SPECIFIC NUCLEIC ACID – CHRONIC FATIGUE SYNDROME CYTOMEGALOVIRUS”[1]. This substance is classified as a nucleic acid, which means it’s related to the genetic material found in our cells[1].

Target Condition: Epstein-Barr Virus Infection

The primary target of this treatment is Epstein-Barr Virus infection[1]. EBV is a common virus that can cause various symptoms, including:

  • Significant fatigue lasting for a month or more
  • Long-lasting exhaustion even after light exertion
  • Subfebrile state (slightly elevated body temperature)
  • Fever
  • Loss of appetite
  • Nausea
  • Sore throat (angina)
  • Sensitive lymph nodes
  • Headaches
  • Muscle pain (myalgia) and weakness
  • Joint pain (arthralgia)
  • Memory and attention problems
  • Sleep disorders
  • Various other symptoms affecting different body systems[1]

Current Clinical Trial

SPECIFIC NUCLEIC ACID SNA-XFSB is currently being studied in a clinical trial as part of a product called 2LXFS[1]. This trial aims to evaluate the effectiveness of 2LXFS in reducing fatigue and other symptoms in patients with EBV infection[1]. The study is:

  • Randomized: Participants are randomly assigned to different groups
  • Placebo-controlled: Some participants receive a placebo (inactive substance) for comparison
  • Double-blind: Neither the participants nor the researchers know who is receiving the actual treatment or placebo[1]

Potential Benefits

The main goal of the treatment is to reduce fatigue severity in patients with EBV infection[1]. Additionally, the study aims to assess improvements in:

  • Other dimensions of fatigue (physical, mental, reduced activity, and motivation)
  • Other EBV-related symptoms
  • Immune system function (through lymphocyte typing and immunoglobulin levels)[1]

Administration and Dosage

2LXFS, which contains SPECIFIC NUCLEIC ACID SNA-XFSB, is administered as pillules for oromucosal use (in the mouth)[1]. The maximum daily dose is 380 mg, with a total treatment amount of 68.4 g over a 6-month period[1].

Other Components in the Treatment

2LXFS contains several other active substances alongside SPECIFIC NUCLEIC ACID SNA-XFSB, including:

  • Interferon alfa and gamma
  • Interleukin-1 and 2
  • Various types of ribonucleic acid (RNA)
  • Other specific nucleic acids (SNA-XFSA and SNA-XFSC)
  • Tumor necrosis factor-alpha[1]

These components are believed to work together to potentially improve the immune response against EBV infection.

Conclusion

SPECIFIC NUCLEIC ACID SNA-XFSB, as part of the 2LXFS treatment, is being studied as a potential therapy for Epstein-Barr Virus infection. While the results of the clinical trial are not yet known, this research may provide valuable insights into managing EBV-related fatigue and other symptoms. As with any experimental treatment, it’s important to consult with healthcare professionals and await the results of properly conducted clinical trials before drawing conclusions about its effectiveness and safety.

Aspect Details
Study Type Randomized, placebo-controlled, double-blind clinical trial
Drugs Tested 2LEBV® and 2LXFS®
Target Condition Fatigue in Epstein-Barr Virus (EBV) infection
Primary Outcome Fatigue severity at 6 months (end of treatment)
Secondary Outcomes Other EBV symptoms, lymphocyte typing, IgG levels, safety
Participant Age 12 years and older
Study Duration 12 months (including 6 months of treatment)
Key Inclusion Criteria Significant fatigue for 1+ month, 2+ other EBV symptoms, positive EBV serology
Key Exclusion Criteria Recent homeopathic treatments, immunosuppressive therapy, severe immunodeficiency

FAQ

  • What is the main goal of this clinical trial? The main goal is to compare the effectiveness of 2LEBV® or 2LXFS®/2LEBV® against a placebo in reducing fatigue severity at the end of the treatment period for patients with Epstein-Barr Virus infection.
  • Who can participate in this study? Participants must be 12 years or older, experiencing significant fatigue for at least a month, have at least two other EBV-related symptoms, and test positive for EBV antibodies. They should not have received certain treatments recently and must not have severe immunodeficiency diseases.
  • How long does the study last? The study includes follow-up visits at 3 months, 6 months (end of treatment), and 12 months after starting the treatment.
  • What measurements will be taken during the study? The study will measure fatigue using the MFI-20 questionnaire, assess other EBV-related symptoms, perform lymphocyte typing, check immune status, and monitor IgG antibody levels. Safety will also be evaluated by tracking adverse events.
  • What is special about the drug 2LXFS®? 2LXFS® contains various substances including interferons, interleukins, specific nucleic acids, and tumor necrosis factor-alpha. It is designed to target the immune system and potentially help with EBV-related symptoms.

Ongoing Clinical Trials on Specific Nucleic Acid Sna-Xfsb

  • Study on the Effectiveness of 2LEBV and 2LXFS for Reducing Fatigue in Patients with Epstein-Barr Virus Infection

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Epstein-Barr Virus (EBV): A common virus that can cause infectious mononucleosis and is associated with certain cancers. It often leads to fatigue and other symptoms.
  • Asthenia: A medical term for weakness or lack of energy, which is a common symptom in EBV infections.
  • Placebo: A substance with no active therapeutic effect, used as a control in testing new drugs.
  • Double-blind study: A study where neither the participants nor the researchers know who is receiving the actual treatment and who is receiving a placebo.
  • MFI-20 questionnaire: A tool used to measure fatigue in patients, assessing different aspects of fatigue.
  • Lymphocyte typing: A test that identifies and counts different types of white blood cells, which are important for immune function.
  • IgG and IgM: Types of antibodies produced by the immune system in response to infections.
  • Immunosuppressive treatment: Medications that lower the body's immune response, often used to treat autoimmune diseases or prevent organ rejection after transplants.
  • Micro-immunotherapy: A type of therapy that aims to regulate the immune system using very low doses of immune messengers.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-2lebv-and-2lxfs-for-reducing-fatigue-in-patients-with-epstein-barr-virus-infection/